Becton, Dickinson and Rating Reiterated by Morgan Stanley (BDX)
Becton, Dickinson and (NYSE:BDX)‘s stock had its “hold” rating restated by investment analysts at Morgan Stanley in a note issued to investors on Friday. They currently have a $123.00 price target on the stock, up from their previous price target of $119.00. Morgan Stanley’s price objective would suggest a potential upside of 5.82% from the company’s current price.
The analysts wrote, “BD continues to deliver though valuation mostly captures prospects. BD’s F3Q14 sales and EPS came in slightly ahead of Consensus expectations though the company maintained its FY14 guidance. Becton has had fairly consistent results over the past several quarters and we believe constant currency sales growth of 4.5%-5.0% is sustainable. With operating margin expansion and tax rate management, we expect BDX to sustain a double-digit EPS growth profile. While we like the fundamental prospects for the company, we believe the relative valuation does mostly reflect it. We maintain our Hold rating.”
A number of other analysts have also recently weighed in on BDX. Analysts at Canaccord Genuity raised their price target on shares of Becton, Dickinson and from $110.00 to $113.00 in a research note on Friday. Separately, analysts at ISI Group raised their price target on shares of Becton, Dickinson and from $126.50 to $127.50 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Becton, Dickinson and from $112.00 to $115.00 in a research note on Monday, June 30th. They now have an “underweight” rating on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $111.25.
Shares of Becton, Dickinson and (NYSE:BDX) traded up 0.09% during mid-day trading on Friday, hitting $116.35. The stock had a trading volume of 108,697 shares. Becton, Dickinson and has a 52 week low of $96.73 and a 52 week high of $120.66. The stock’s 50-day moving average is $118.7 and its 200-day moving average is $115.3. The company has a market cap of $22.479 billion and a price-to-earnings ratio of 24.25.
Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $1.65 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.67 by $0.02. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. Analysts expect that Becton, Dickinson and will post $6.25 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, September 30th. Investors of record on Tuesday, September 9th will be given a dividend of $0.545 per share. This represents a $2.18 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Friday, September 5th.
Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.